Evidence map›Paper›PMID 31783119›Full record

ArticleNeurobiology of disease2020

Druggable genome screen identifies new regulators of the abundance and toxicity of ATXN3, the Spinocerebellar Ataxia type 3 disease protein.

Naila S Ashraf, Joanna R Sutton, Yemen Yang, Bedri Ranxhi, Kozeta Libohova, Emily D Shaw, Anna J Barget, Sokol V Todi, Henry L Paulson, Maria do Carmo Costa

Open access · hybridAbstract read
In one paragraph

Article in Neurobiology of disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
0.7field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Decoding Nucleotide Repeat Expansion Diseases: Novel Insights fromInternational journal of molecular sciences · 2024
    Review
  8. Article
  9. Article
  10. Review
  11. Progressive degeneration in a newResearch square · 2023
    Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Naila S AshrafDepartment of Neurology, Michigan Medicine, University of Michigan, Ann Arbor, MI, USA.
Joanna R SuttonDepartment of Pharmacology, Wayne State University School of Medicine, Detroit, MI, USA.
Yemen YangDepartment of Neurology, Michigan Medicine, University of Michigan, Ann Arbor, MI, USA.
Bedri RanxhiDepartment of Pharmacology, Wayne State University School of Medicine, Detroit, MI, USA.
Kozeta LibohovaDepartment of Pharmacology, Wayne State University School of Medicine, Detroit, MI, USA.
Emily D ShawDepartment of Neurology, Michigan Medicine, University of Michigan, Ann Arbor, MI, USA.
Anna J BargetDepartment of Neurology, Michigan Medicine, University of Michigan, Ann Arbor, MI, USA.
Sokol V TodiDepartment of Pharmacology, Wayne State University School of Medicine, Detroit, MI, USA; Department of Neurology, Wayne State University School of Medicine, Detroit, MI, USA.
Henry L PaulsonDepartment of Neurology, Michigan Medicine, University of Michigan, Ann Arbor, MI, USA. Electronic address: henryp@med.umich.edu.
Maria do Carmo CostaDepartment of Neurology, Michigan Medicine, University of Michigan, Ann Arbor, MI, USA. Electronic address: mariadoc@med.umich.edu.
Michigan Medicine · USWayne State University · US

Funding

Mechanisms of Polyglutamine NeurodegenerationR01NS038712 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI PAULSON, HENRY L · 2000 to 2019
$8.1M
Supplementary funding for U01NS104326 Clinical Trial Readiness for SCA1 and SCA3 (“READISCA”)U01NS104326 · NINDS · METHODIST HOSPITAL RESEARCH INSTITUTE · PI ASHIZAWA, TETSUO, DURR, ALEXANDRA · 2018 to 2022
$6.1M
Protection against Alzheimer's Disease proteins by novel ubiquitin processesR01NS086778 · NINDS · WAYNE STATE UNIVERSITY · PI Sokol Todi · 2014 to 2026
$4.9M
NINDS NIH HHS R01 NS038712NINDS NIH HHS R01 NS086778NINDS NIH HHS U01 NS104326
6 · The paper itself

Abstract

Spinocerebellar Ataxia type 3 (SCA3, also known as Machado-Joseph disease) is a neurodegenerative disorder caused by a CAG repeat expansion encoding an abnormally long polyglutamine (polyQ) tract in the disease protein, ataxin-3 (ATXN3). No preventive treatment is yet available for SCA3. Because SCA3 is likely caused by a toxic gain of ATXN3 function, a rational therapeutic strategy is to reduce mutant ATXN3 levels by targeting pathways that control its production or stability. Here, we sought to identify genes that modulate ATXN3 levels as potential therapeutic targets in this fatal disorder. We screened a collection of siRNAs targeting 2742 druggable human genes using a cell-based assay based on luminescence readout of polyQ-expanded ATXN3. From 317 candidate genes identified in the primary screen, 100 genes were selected for validation. Among the 33 genes confirmed in secondary assays, 15 were validated in an independent cell model as modulators of pathogenic ATXN3 protein levels. Ten of these genes were then assessed in a Drosophila model of SCA3, and one was confirmed as a key modulator of physiological ATXN3 abundance in SCA3 neuronal progenitor cells. Among the 15 genes shown to modulate ATXN3 in mammalian cells, orthologs of CHD4, FBXL3, HR and MC3R regulate mutant ATXN3-mediated toxicity in fly eyes. Further mechanistic studies of one of these genes, FBXL3, encoding a F-box protein that is a component of the SKP1-Cullin-F-box (SCF) ubiquitin ligase complex, showed that it reduces levels of normal and pathogenic ATXN3 in SCA3 neuronal progenitor cells, primarily via a SCF complex-dependent manner. Bioinformatic analysis of the 15 genes revealed a potential molecular network with connections to tumor necrosis factor-α/nuclear factor-kappa B (TNF/NF-kB) and extracellular signal-regulated kinases 1 and 2 (ERK1/2) pathways. Overall, we identified 15 druggable genes with diverse functions to be suppressors or enhancers of pathogenic ATXN3 abundance. Among identified pathways highlighted by this screen, the FBXL3/SCF axis represents a novel molecular pathway that regulates physiological levels of ATXN3 protein.

Indexed as

Ataxin-3HumansMachado-Joseph DiseaseMi-2 Nucleosome Remodeling and Deacetylase ComplexNerve Tissue ProteinsNeurodegenerative DiseasesNeuronsRepressor ProteinsAtaxin-3ATXN3 protein, humanCHD4 protein, humanMi-2 Nucleosome Remodeling and Deacetylase ComplexNerve Tissue ProteinsRepressor ProteinsDrosophilaHigh-throughput screenHuman embryonic stem cellsMachado-Joseph diseaseNeurodegenerationPolyglutamineSpinocerebellar ataxia

Identifiers

PMID31783119
PMCPMC7050396
OpenAlexW2989840905

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.